2018年10月9日 · A third-generation CAR containing 4-1BB, CD3ζ and the C terminus of CD6 (4-1BBz-CD6) enhanced interferon-γ release and cytotoxicity when compared with the second-generation 4-1BB CD3ζ (4-1BBz) CAR. The CD6 C terminus is a valuable addition to potential components for modular design of CARs to improve effector function, particularly cytotoxicity.

Here, we constructed a CAR based on the extracellular domain of CD6 and demonstrate its cytotoxic effect in target positive human CRC cell lines. Unexpectedly, we found that CD6-CAR-T cells targeted CD166 instead of CD318.

CD6 has been exploited as a drug target as its expression is restricted, primarily to T cells, it has a well characterised cell surface ligand, CD166 and regulates T cell activation through a long cytoplasmic tail.

Specificity can be engineered by the addition of chimeric antigen receptors (CARs), with new techniques designed to fine-tune specificity (tandem chimeric antigen receptors, universal chimeric antigen receptors, synNotch chimeric antigen receptors).

2023年12月15日 · Targeted immunotherapies, such as adoptive transfer of immune cells engineered to express chimeric antigen-specific receptors (CARs), have also gained recent interest due to its efficacy against haematological malignancies [10].

This phase I trial tests the safety, side effects, and best dose of allogeneic CD6 chimeric antigen receptor T regulatory cells (CD6-CAR Tregs) in treating patients who have chronic graft versus host disease (cGVHD) after an allogeneic hematopoietic cell transplantation (HCT).

2021年3月8日 · The combined capability of an anti-CD6 monoclonal antibody to control autoimmunity through effects on CD4+ lymphocyte differentiation while enhancing killing of cancer cells through distinct effects on CD8+ and NK cells opens a potential new approach to cancer immunotherapy that would suppress rather than instigate autoimmunity.

Unpublished preliminary in vitro observations made by our group using human leukemic NK cell-derived KHYG-1 cells stably transduced with a second-generation CD6-CAR also show superior cytotoxic activity against high CD166/ALCAM-expressing human cancer cell lines from colon (DLD-1) and ovary (SKOV-3) origin, compared to the control non ...

This phase I trial tests the safety, side effects, and best dose of allogeneic CD6 chimeric antigen receptor T regulatory cells (CD6-CAR Tregs) in treating patients who have chronic graft versus host disease (cGVHD) after an allogeneic hematopoietic cell transplantation (HCT).

A preparation of allogeneic T-regulatory cells (Tregs) that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the T-cell differentiation antigen CD6, with potential immunmodulating activity.